loading
Schlusskurs vom Vortag:
$13.94
Offen:
$13.68
24-Stunden-Volumen:
41,717
Relative Volume:
0.36
Marktkapitalisierung:
$203.06M
Einnahmen:
$3.25M
Nettoeinkommen (Verlust:
$-116.80M
KGV:
-4.2557
EPS:
-3.05
Netto-Cashflow:
$-98.17M
1W Leistung:
+26.88%
1M Leistung:
+57.91%
6M Leistung:
+37.50%
1J Leistung:
-48.66%
1-Tages-Spanne:
Value
$12.74
$14.09
1-Wochen-Bereich:
Value
$10.35
$14.09
52-Wochen-Spanne:
Value
$5.6652
$27.84

Rapt Therapeutics Inc Stock (RAPT) Company Profile

Name
Firmenname
Rapt Therapeutics Inc
Name
Telefon
(650) 489-9000
Name
Adresse
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Name
Mitarbeiter
67
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
RAPT's Discussions on Twitter

Vergleichen Sie RAPT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RAPT
Rapt Therapeutics Inc
12.98 203.06M 3.25M -116.80M -98.17M -3.05
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.83 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
571.29 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.14 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
588.61 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.96 31.99B 3.81B -644.79M -669.77M -6.24

Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-22 Fortgesetzt H.C. Wainwright Buy
2024-12-26 Hochstufung H.C. Wainwright Neutral → Buy
2024-11-13 Herabstufung Stifel Buy → Hold
2024-11-11 Herabstufung JP Morgan Neutral → Underweight
2024-11-11 Herabstufung Piper Sandler Overweight → Neutral
2024-05-14 Herabstufung Wolfe Research Outperform → Peer Perform
2024-05-10 Herabstufung Barclays Overweight → Equal Weight
2024-05-10 Herabstufung Guggenheim Buy → Neutral
2024-02-22 Herabstufung UBS Buy → Neutral
2024-02-21 Herabstufung H.C. Wainwright Buy → Neutral
2024-02-21 Herabstufung JP Morgan Overweight → Neutral
2024-02-21 Herabstufung Leerink Partners Outperform → Market Perform
2024-02-20 Herabstufung Cantor Fitzgerald Overweight → Neutral
2024-02-16 Eingeleitet Evercore ISI Outperform
2024-02-15 Eingeleitet Wolfe Research Outperform
2023-09-14 Eingeleitet Berenberg Buy
2023-08-09 Eingeleitet Stifel Buy
2023-06-15 Eingeleitet Barclays Overweight
2023-01-04 Eingeleitet Guggenheim Buy
2022-12-01 Eingeleitet Goldman Buy
2022-09-21 Eingeleitet CapitalOne Overweight
2022-05-24 Fortgesetzt Cantor Fitzgerald Overweight
2021-12-09 Eingeleitet JP Morgan Overweight
2021-08-12 Eingeleitet SVB Leerink Outperform
2021-06-21 Eingeleitet Piper Sandler Overweight
2020-06-01 Eingeleitet H.C. Wainwright Buy
2020-05-19 Eingeleitet Cantor Fitzgerald Overweight
2020-04-13 Eingeleitet ROTH Capital Buy
2019-11-25 Eingeleitet BMO Capital Markets Outperform
2019-11-25 Eingeleitet UBS Buy
2019-11-25 Eingeleitet Wells Fargo Outperform
Alle ansehen

Rapt Therapeutics Inc Aktie (RAPT) Neueste Nachrichten

pulisher
Jul 23, 2025

Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Rating of “Hold” from Analysts - Defense World

Jul 23, 2025
pulisher
Jul 23, 2025

RAPT Therapeutics Inc. Stock Analysis and ForecastPhenomenal capital gains - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

What drives RAPT Therapeutics Inc. stock pricePhenomenal trading returns - Autocar Professional

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about RAPT Therapeutics Inc. stockFree Stock Selection - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

RAPT Therapeutics: LifeSci Capital initiates Outperform with $31 PT. - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

What makes RAPT Therapeutics Inc. stock price move sharplyFree Access to Investment Community - Newser

Jul 22, 2025
pulisher
Jul 19, 2025

Is RAPT Therapeutics Inc. a good long term investmentHigh-performance investment picks - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 15, 2025

How RAPT Therapeutics Inc. stock performs during market volatilityTop Performer Shortlist - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why RAPT Therapeutics Inc. stock attracts strong analyst attentionSafe Entry High Exit Alerts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

RAPT Therapeutics Explodes 20%—What's Fueling the Surge? - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

RAPT Therapeutics Soars 24%—What’s Fueling the Breakout? - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Best Momentum Stocks to Buy for July 15th - TradingView

Jul 15, 2025
pulisher
Jul 15, 2025

Does Rapt Therapeutics (RAPT) Have the Potential to Rally 183.83% as Wall Street Analysts Expect? - Yahoo Finance

Jul 15, 2025
pulisher
Jul 14, 2025

HC Wainwright Analysts Decrease Earnings Estimates for RAPT - Defense World

Jul 14, 2025
pulisher
Jul 12, 2025

HC Wainwright Forecasts Strong Price Appreciation for Rapt Therapeutics (NASDAQ:RAPT) Stock - Defense World

Jul 12, 2025
pulisher
Jul 12, 2025

Rapt Therapeutics (NASDAQ:RAPT) Price Target Raised to $27.00 - Defense World

Jul 12, 2025
pulisher
Jul 11, 2025

H.C. Wainwright Maintains RAPT Therapeutics(RAPT.US) With Buy Rating, Cuts Target Price to $27 - 富途牛牛

Jul 11, 2025
pulisher
Jul 08, 2025

RAPT Therapeutics Unveils Plans for RPT904 Development - TipRanks

Jul 08, 2025
pulisher
Jun 28, 2025

Rapt Therapeutics (NASDAQ:RAPT) Given Average Rating of “Hold” by Analysts - Defense World

Jun 28, 2025
pulisher
Jun 23, 2025

RAPT Therapeutics Expands Board with New Appointments - TipRanks

Jun 23, 2025
pulisher
Jun 18, 2025

Wall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Here's What You Should Know - Yahoo Finance

Jun 18, 2025
pulisher
Jun 17, 2025

RAPT Therapeutics Executes 1-for-8 Reverse Stock Split - TipRanks

Jun 17, 2025
pulisher
Jun 16, 2025

RAPT Therapeutics (RAPT) Trading Halted as News Awaits Release | RAPT Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace

Jun 16, 2025
pulisher
Jun 14, 2025

Rapt Therapeutics announces effective date for 1-for-8 reverse stock split - Yahoo Finance

Jun 14, 2025
pulisher
Jun 13, 2025

# RAPT Therapeutics to implement 1-for-8 reverse stock split By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

RAPT Finalizes Reverse Split Plan; 1-for-8 Ratio Effective June 16, 2025 - Nasdaq

Jun 13, 2025
pulisher
Jun 13, 2025

RAPT Therapeutics Shares to Start Trading on a Split-Adjusted Basis Tuesday - marketscreener.com

Jun 13, 2025
pulisher
Jun 13, 2025

RAPT Therapeutics Announces Effective Date For 1-For-8 Reverse Stock Split - MarketScreener

Jun 13, 2025
pulisher
Jun 13, 2025

RAPT Therapeutics Announces Reverse Stock Split Effective June 2025 | RAPT Stock News - GuruFocus

Jun 13, 2025

Finanzdaten der Rapt Therapeutics Inc-Aktie (RAPT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$23.62
price up icon 3.28%
$36.59
price up icon 1.62%
$103.43
price up icon 0.09%
$27.66
price down icon 1.21%
$113.95
price down icon 0.57%
biotechnology ONC
$296.05
price up icon 0.44%
Kapitalisierung:     |  Volumen (24h):